+

PE20020885A1 - Compuestos de quinazol como inhibidores de mmp - Google Patents

Compuestos de quinazol como inhibidores de mmp

Info

Publication number
PE20020885A1
PE20020885A1 PE2002000115A PE2002000115A PE20020885A1 PE 20020885 A1 PE20020885 A1 PE 20020885A1 PE 2002000115 A PE2002000115 A PE 2002000115A PE 2002000115 A PE2002000115 A PE 2002000115A PE 20020885 A1 PE20020885 A1 PE 20020885A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
compounds
benzyl
quinazole
Prior art date
Application number
PE2002000115A
Other languages
English (en)
Inventor
Charles Andrianjara
Henry Jacobelli
Bernard Gaudilliere
Francine Breuzard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20020885A1 publication Critical patent/PE20020885A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A QUINAZOLINAS DE FORMULA I DONDE W ES N, CR1; R1 ES H, OR5, SR5, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, ENTRE OTROS, X ES N, CR2; R2 ES H, NR6R7, OR6, ENTRE OTROS; R6 Y R7 SON H, ALQUILO C1-C6, ENTRE OTROS; Y ES O, S, NH, N-ALQUILO C1-C6; Z ES O, S, Y-NR8; R8 ES H, ALQUILO C1-C6, ARILO, ENTRE OTROS; Z ES UN ATOMO DE CARBONO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C6, ARILO, ENTRE OTROS; n ES 0-8; Z1 ES CR9R10; R9 Y R10 SON H, ALQUILO C1-C6, HALOGENO, NR5R11, ENTRE OTROS; R5 Y R11 SON H, ALQUILO C1-C6; A ES UN MONOCICLO, BICICLO AROMATICO O NO AROMATICO; m ES 0-7; R4 ES ALQUILO C1-C6, HALOGENO, CN, NO2, SCF3C, ENTRE OTROS; X1 ES O, S OPCIONALMENTE SUSTITUIDO O, N; k ES 0-3; R5 Y R11 SON H, ALQUILO C1-C6; X2 ES UN ENLACE, CH2, O, S; R12 ES UN HETEROCICLO, NO HETEROCICLO; R3 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, UN GRUPO a, ENTRE OTROS; p ES 0-8; Z2 ES CR14R15; R14 Y R15 SON H, ALQUILO C1-C6, FENILO, ENTRE OTROS; B ES MONOCICLO, BICICLO; q ES 0-7; R13 ES ALQUILO C1-C6, HALOGENO, CN, NO2, ENTRE OTROS; q ES 0-7; R13 ES ALQUILO C1-C6, HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS BENCIL 4-BENCIL-5-OXO-4H-[1,2,4]TRIAZOL[4,3-a]QUINAZOL-7-ILCARBOXILATO, 4-PIRIDILMETIL 4-BENCIL-5-OXO-4H-[1,2,4]TRIAZOL[4,3-a]QUINAZOL-ILCARBOXILATO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ARTRITIS, ARTRITIS REUMATICA, OSTEOARTRITIS, OSTEOPOROSIS
PE2002000115A 2001-02-14 2002-02-13 Compuestos de quinazol como inhibidores de mmp PE20020885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26875701P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
PE20020885A1 true PE20020885A1 (es) 2002-10-26

Family

ID=23024335

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000115A PE20020885A1 (es) 2001-02-14 2002-02-13 Compuestos de quinazol como inhibidores de mmp

Country Status (15)

Country Link
US (1) US6849637B2 (es)
EP (1) EP1362048B1 (es)
JP (1) JP2004521908A (es)
AR (1) AR032677A1 (es)
AT (1) ATE294805T1 (es)
BR (1) BR0207270A (es)
CA (1) CA2437588A1 (es)
DE (1) DE60203995T2 (es)
ES (1) ES2239216T3 (es)
HN (1) HN2002000038A (es)
MX (1) MXPA03007249A (es)
PA (1) PA8539501A1 (es)
PE (1) PE20020885A1 (es)
SV (1) SV2002000875A (es)
WO (1) WO2002064595A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
CA2495432A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003247024A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
JP2006502114A (ja) * 2002-07-17 2006-01-19 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリクスメタロプロテイナーゼ−１３のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ
AU2003281167A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
EP1539709A1 (en) 2002-08-13 2005-06-15 Warner-Lambert Company LLC Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
AU2002368151A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
EP1537098A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
MXPA05001784A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de isoquinolina como inhibidores de metaloproteinasa de matriz.
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
ES2283851T3 (es) 2002-08-13 2007-11-01 Warner-Lambert Company Llc Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz.
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
EP1910367A2 (en) * 2005-05-20 2008-04-16 Alantos Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7795877B2 (en) * 2006-11-02 2010-09-14 Current Technologies, Llc Power line communication and power distribution parameter measurement system and method
AU2007321924A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
DE102010031945A1 (de) * 2010-07-22 2012-01-26 Osram Opto Semiconductors Gmbh Halbleiterbauelement und Verfahren zur Herstellung eines Halbleiterbauelements
JP2014501790A (ja) 2011-01-10 2014-01-23 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノンの調製方法及びイソキノリノンの固体形態
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6584952B2 (ja) 2012-11-01 2019-10-02 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
CN115197225B (zh) * 2021-09-03 2023-04-11 贵州大学 一种五元杂环并喹唑啉酮类化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
EP0217748B1 (en) * 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
EP1028716A1 (en) 1996-12-09 2000-08-23 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
HN2000000137A (es) 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
SK4972003A3 (en) 2000-10-26 2004-05-04 Pfizer Prod Inc 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
EE200300195A (et) 2000-10-26 2003-10-15 Pfizer Products Inc. Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
WO2003032999A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2463159A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
AU2002249275A1 (en) 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US6747147B2 (en) * 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
WO2004000321A1 (en) 2002-06-25 2003-12-31 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
AU2003249539A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ATE294805T1 (de) 2005-05-15
BR0207270A (pt) 2004-02-10
US6849637B2 (en) 2005-02-01
DE60203995T2 (de) 2005-09-22
DE60203995D1 (de) 2005-06-09
HN2002000038A (es) 2002-09-05
ES2239216T3 (es) 2005-09-16
AR032677A1 (es) 2003-11-19
SV2002000875A (es) 2002-10-04
US20020151558A1 (en) 2002-10-17
PA8539501A1 (es) 2002-09-30
JP2004521908A (ja) 2004-07-22
CA2437588A1 (en) 2002-08-22
EP1362048B1 (en) 2005-05-04
EP1362048A1 (en) 2003-11-19
WO2002064595A1 (en) 2002-08-22
MXPA03007249A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
PE20020885A1 (es) Compuestos de quinazol como inhibidores de mmp
EP1487428A4 (en) (E) - 2,6-DIALCOXYSTYRYL SUBSTITUTED AMINO-BENZYLSULFONES SUBSTITUTED IN POSITION 4 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
PE20041000A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
ATE433981T1 (de) Heterocyclische verbindungen
EA200800873A1 (ru) Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы
PE20030010A1 (es) Triazolopiridinas como inhibidores de quinasas
PE20091371A1 (es) Inhibidores de hsp90
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
PE20041076A1 (es) Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
PE20061424A1 (es) Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos
CY1109322T1 (el) Παραγωγα προλινης και η χρηση τους ως αναστολεις διπεπτιδυλικης πεπτιδασης iv
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
CY1107468T1 (el) Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχους
CY1111349T1 (el) Καρβαμιδικες ενωσεις προς χρηση στη θεραπεια του πονου
ECSP066632A (es) El uso de derivados de n-arilhidrazina para combatir pestes en y sobre animales
ATE401311T1 (de) Kondensierte heterozyklische verbindungen als petidase inhibitoren
HK1053463A1 (en) Aminobenzophenones as inhibitors of il-1B and TNF-a.
DE60333746D1 (de) Thienylverbindungen
CY1107149T1 (el) Νεα παραγωγα αμιδινοβενζυλαμινης και χρηση τους ως αναστολεων θρομβινης
CY1114865T1 (el) Νεοι αναστολεις seh και η χρηση toyς
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
DE60014393D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
EA200800295A1 (ru) Способы лечения эпилептогенеза

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载